S
SPRY icon

SignatureFD’s ARS Pharmaceuticals SPRY Stock Holding History

SignatureFD’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.7K Buy
3,212
+400
+14% +$3.44K ﹤0.01% 2220
2026
Q1 		$22.6K Hold
2,812
– – ﹤0.01% 2146
2025
Q4 		$32.8K Hold
2,812
– – ﹤0.01% 1881
2025
Q3 		$28.3K Hold
2,812
– – ﹤0.01% 1940
2025
Q2 		$49.1K Hold
2,812
– – ﹤0.01% 1593
2025
Q1 		$35.4K Sell
2,812
-144
-5% -$1.73K ﹤0.01% 1762
2024
Q4 		$31.2K Buy
2,956
+144
+5% +$2.02K ﹤0.01% 1830
2024
Q3 		$40.8K Hold
2,812
– – ﹤0.01% 1691
2024
Q2 		$23.9K Hold
2,812
– – ﹤0.01% 1876
2024
Q1 		$28.7K Hold
2,812
– – ﹤0.01% 1819
2023
Q4 		$15.4K Buy
2,812
+2,563
+1,029% +$11.2K ﹤0.01% 2055
2023
Q3 		$941 Buy
249
+137
+122% +$899 ﹤0.01% 2945
2023
Q2 		$750 Buy
+112
New +$748 ﹤0.01% 3023
2021
Q4 		– Sell
-66
Closed -$1K – 3264
2021
Q3 		$1K Buy
66
+22
+50% +$543 ﹤0.01% 2924
2021
Q2 		$1K Buy
+44
New +$1.41K ﹤0.01% 2827

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

SignatureFD's SPRY Position: Q2 2026 in Review

SignatureFD increased its ARS Pharmaceuticals (SPRY) stake by 14% in Q2 2026, buying an estimated $3.44K and bringing the position to 3,212 shares worth $25.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2220.

SignatureFD first reported a position in SPRY in Q2 2021 and has held it in 15 quarters since. The position peaked at $49.1K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • SignatureFD held 3,212 shares of ARS Pharmaceuticals worth $25.7K as of Q2 2026.
  • SignatureFD bought 400 ARS Pharmaceuticals shares in Q2 2026, an estimated $3.44K.
  • ARS Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2220 holding.
  • SignatureFD first reported a position in ARS Pharmaceuticals in Q2 2021 and has held it in 15 quarters since.
  • SignatureFD's ARS Pharmaceuticals position peaked at $49.1K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.